Olmesartan/amlodipine/hydrochlorothiazide Cinfa 40 mg/10 mg/12.5 mg film-coated tablets EFG

Patient Information Leaflet

Introduction

Patient Information Leaflet

olmesartán/amlodipino/hidroclorotiazida cinfa 40 mg/10 mg/12.5 mg film-coated tablets EFG

olmesartan medoxomil / amlodipine / hydrochlorothiazide

Read the entire leaflet carefully before you start taking this medicine, as it contains important information for you.

• Keep this leaflet, as you may need to read it again.
• If you have any questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only, and you should not give it to others, even if they have the same symptoms as you, because it could harm them.
• If you experience any adverse effects, consult your doctor or pharmacist, even if they are effects not listed in this leaflet. See section 4.

Leaflet Contents

1. What olmesartán/amlodipino/hidroclorotiazida cinfa is and what it is used for
2. What you need to know before taking olmesartán/amlodipino/hidroclorotiazida cinfa
3. How to take olmesartán/amlodipino/hidroclorotiazida cinfa
4. Possible side effects
5. How to store olmesartán/amlodipino/hidroclorotiazida cinfa
6. Contents of the pack and other information

1. What Olmesartan/Amlodipine/Hydrochlorothiazide Cinfa is and what it is used for

This medicine contains three active substances: olmesartan medoxomil, amlodipine (as amlodipine besilate), and hydrochlorothiazide. The three substances help control high blood pressure.

• Olmesartan medoxomil belongs to a group of medicines called "angiotensin II receptor antagonists", which lower blood pressure by relaxing blood vessels.
• Amlodipine belongs to a group of medicines called "calcium channel blockers". Amlodipine also lowers blood pressure by relaxing blood vessels.
• Hydrochlorothiazide belongs to a group of medicines called thiazide diuretics. It lowers blood pressure by helping the body get rid of excess fluid, increasing urine production by the kidneys.

The combined action of these substances helps reduce your blood pressure. Olmesartan/hydrochlorothiazide/amlodipine is used to treat high blood pressure:

• in adult patients whose blood pressure is not adequately controlled with the combination of olmesartan medoxomil and amlodipine taken as a fixed-dose combination, or
• in adult patients who are already taking a fixed-dose combination of olmesartan medoxomil and hydrochlorothiazide together with tablets containing amlodipine only, or a fixed-dose combination of olmesartan medoxomil and amlodipine together with tablets containing hydrochlorothiazide only.

2. What you need to know before taking olmesartan/amlodipine/hydrochlorothiazide cinfa

Do not take olmesartan/amlodipine/hydrochlorothiazide cinfa

• If you are allergic to olmesartan medoxomil, amlodipine, or a specific group of calcium channel blockers (dihydropyridines), hydrochlorothiazide, substances similar to hydrochlorothiazide (sulfonamides), or any of the other components of this medicine (listed in section 6).
• If you think you may be allergic, inform your doctor before taking olmesartan/amlodipine/hydrochlorothiazide cinfa.
• If you have severe kidney problems.
• If you have diabetes or renal failure and are being treated with a blood pressure-lowering medicine containing aliskiren.
• If you have low levels of potassium or sodium in your blood, high levels of calcium or uric acid (with symptoms of gout or kidney stones) in your blood that do not improve with treatment.
• If you are more than 3 months pregnant. (It is also advisable to avoid olmesartan/amlodipine/hydrochlorothiazide cinfa in early pregnancy – see section “Pregnancy and breastfeeding”).
• If you have severe liver problems, bile secretion disorders, or obstruction of bile drainage from the gallbladder (e.g., due to gallstones), or have jaundice (yellowing of the skin and eyes).
• If you have inadequate blood supply to your tissues, with symptoms such as low blood pressure, weak pulse, rapid heartbeat, or shock (including cardiogenic shock, meaning shock due to serious heart problems).
• If you have very low blood pressure.
• If blood flow from your heart is slow or blocked. This may occur if blood vessels or valves carrying blood away from the heart are narrowed (aortic stenosis).
• If you have low cardiac output following a heart attack (acute myocardial infarction). Low cardiac output may cause shortness of breath or swelling in your feet and ankles.

Do not take olmesartan/amlodipine/hydrochlorothiazide cinfa if any of the above apply to you.

Warnings and precautions

Talk to your doctor or pharmacist before taking olmesartan/amlodipine/hydrochlorothiazide cinfa.

Tell your doctor if you are taking any of the following medicines used to treat high blood pressure (hypertension):

• An angiotensin-converting enzyme (ACE) inhibitor (e.g., enalapril, lisinopril, ramipril), especially if you have kidney problems related to diabetes.
• Aliskiren.

Your doctor may monitor your kidney function, blood pressure, and blood electrolyte levels (e.g., potassium) at regular intervals.

See also the information under the heading “Do not take olmesartan/amlodipine/hydrochlorothiazide cinfa”.

Tell your doctor if you have any of the following health conditions:

• Kidney problems or a kidney transplant.
• Liver disease.
• Heart failure or problems with heart valves or heart muscle.
• Severe vomiting, diarrhea, treatment with high doses of medicines that increase urine output (diuretics), or if you are on a low-salt diet.
• High levels of potassium in your blood.
• Problems with your adrenal glands (hormone-producing glands located above the kidneys).
• Diabetes.
• If you experience vision loss or eye pain, these could be symptoms of fluid accumulation in the vascular layer of the eye (choroidal effusion) or increased eye pressure, which may occur within hours to a week after taking olmesartan/amlodipine/hydrochlorothiazide cinfa.
• Lupus erythematosus (an autoimmune disease).
• Allergy or asthma.
• Skin reactions such as sunburn or rash after sun exposure or use of tanning beds.
• If you have had skin cancer or develop an unexpected skin lesion during treatment. Treatment with hydrochlorothiazide, particularly long-term use at high doses, may increase the risk of certain types of non-melanoma skin and lip cancers. Protect your skin from sun exposure and UV radiation while taking olmesartan/amlodipine/hydrochlorothiazide cinfa.
• If you have previously experienced breathing or lung problems (such as inflammation or fluid in the lungs) after taking hydrochlorothiazide. If you develop shortness of breath or severe difficulty breathing after taking olmesartan/amlodipine/hydrochlorothiazide cinfa, seek medical help immediately.

Contact your doctor if you experience abdominal pain, nausea, vomiting, or diarrhea after taking olmesartan/amlodipine/hydrochlorothiazide cinfa. Your doctor will decide whether to continue treatment. Do not stop taking olmesartan/amlodipine/hydrochlorothiazide cinfa on your own.

Contact your doctor if you experience any of the following symptoms:

• Severe, persistent diarrhea causing significant weight loss. Your doctor will assess your symptoms and decide how to continue your blood pressure treatment.
• Vision loss or eye pain. These could be symptoms of increased eye pressure and may occur from hours to weeks after taking olmesartan/amlodipine/hydrochlorothiazide cinfa. Untreated, this may lead to permanent vision impairment.

As with any other medicine that lowers blood pressure, excessive reduction in blood pressure in patients with impaired blood flow to the heart or brain may lead to heart attack or stroke. Therefore, your doctor will carefully monitor your blood pressure.

Olmesartan/amlodipine/hydrochlorothiazide cinfa may increase blood levels of lipids and uric acid (which causes gout – painful joint swelling). Your doctor may periodically perform blood tests to monitor these potential changes.

Changes in blood levels of certain chemicals called electrolytes may occur. Your doctor may periodically perform blood tests to monitor this. Signs of electrolyte imbalance include: thirst, dry mouth, muscle pain or cramps, tired muscles, low blood pressure (hypotension), feeling weak, slow, tired, drowsy, restless, nausea, vomiting, reduced need to urinate, or rapid heartbeat. Inform your doctor if you experience any of these symptoms.

If you are scheduled for parathyroid function tests, you must stop taking olmesartan/amlodipine/hydrochlorothiazide cinfa before the tests.

Athletes should be aware that this medicine contains a component that may result in a positive doping test.

Inform your doctor if you are pregnant (or think you might be). Use of olmesartan/amlodipine/hydrochlorothiazide cinfa is not recommended in early pregnancy, and it must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if taken during this stage (see section “Pregnancy and breastfeeding”).

Children and adolescents (under 18 years of age)

The use of olmesartan/amlodipine/hydrochlorothiazide cinfa is not recommended in children and adolescents under 18 years of age.

Taking olmesartan/amlodipine/hydrochlorothiazide cinfa with other medicines

Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any of the following medicines:

• Other blood pressure-lowering medicines, as they may enhance the effect of olmesartan/amlodipine/hydrochlorothiazide cinfa.

Your doctor may need to adjust your dose and/or take other precautions:

• If you are taking an angiotensin-converting enzyme (ACE) inhibitor or aliskiren (see also information under the headings “Do not take olmesartan/amlodipine/hydrochlorothiazide cinfa” and “Warnings and precautions”).
• Lithium (a medicine used to treat mood disorders and certain types of depression) may have increased toxicity when used with olmesartan/amlodipine/hydrochlorothiazide cinfa. If you need to take lithium, your doctor will monitor lithium levels in your blood.
• Diltiazem, verapamil, used for heart rhythm disorders and high blood pressure.
• Rifampicin, erythromycin, clarithromycin, tetracyclines, or sparfloxacin, antibiotics used for tuberculosis and other infections.
• St. John’s wort (Hypericum perforatum), a herbal remedy for depression.
• Cisapride, used to increase gastrointestinal motility.
• Difemanil, used to treat slow heart rate or reduce sweating.
• Halofantrine, used for malaria.
• Vincamine IV, used to improve blood circulation in the nervous system.
• Amantadine, used for Parkinson’s disease.
• Potassium supplements, potassium-containing salt substitutes, diuretics (medicines that increase urine output), heparin (to thin blood and prevent clots), ACE inhibitors (to lower blood pressure), laxatives, steroids, adrenocorticotropic hormone (ACTH), carbenoxolone (a medicine for mouth and stomach ulcers), sodium G penicillin (an antibiotic also known as sodium benzylpenicillin), certain painkillers such as acetylsalicylic acid (“aspirin”) or salicylates. Using these medicines with olmesartan/amlodipine/hydrochlorothiazide cinfa may alter blood potassium levels.
• Non-steroidal anti-inflammatory drugs (NSAIDs) (medicines used to relieve pain, swelling, and other inflammatory symptoms, including arthritis), when used with olmesartan/amlodipine/hydrochlorothiazide cinfa, may increase the risk of kidney failure. The effect of olmesartan/amlodipine/hydrochlorothiazide cinfa may be reduced by NSAIDs. High doses of salicylates may increase central nervous system toxicity.
• Sleep-inducing medicines, sedatives, and antidepressants, when used with olmesartan/amlodipine/hydrochlorothiazide cinfa, may cause a sudden drop in blood pressure upon standing.
• Colesevelam hydrochloride, a medicine that lowers blood cholesterol, may reduce the effect of olmesartan/amlodipine/hydrochlorothiazide cinfa. Your doctor may advise you to take olmesartan/amlodipine/hydrochlorothiazide cinfa at least 4 hours before colesevelam hydrochloride.
• Certain antacids (remedies for indigestion and heartburn), as they may slightly reduce the effect of olmesartan/amlodipine/hydrochlorothiazide cinfa.
• Certain muscle relaxants, such as baclofen and tubocurarine.
• Anticholinergic medicines, such as atropine and biperiden.
• Calcium supplements.
• Dantrolene (intravenous, for severe body temperature abnormalities).
• Simvastatin, used to lower cholesterol and fat (triglyceride) levels in the blood.
• Medicines used to control the body’s immune response (e.g., tacrolimus, cyclosporine), which help the body accept a transplanted organ.

Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any of the following medicines for:

• Treating certain mental disorders, such as thioridazine, chlorpromazine, levomepromazine, trifluoperazine, cyamemazine, sulpiride, amisulpride, pimozide, sultopride, tiapride, droperidol, or haloperidol.
• Treating low blood sugar (e.g., diazoxide) or high blood pressure (e.g., beta-blockers, methyldopa), since olmesartan/amlodipine/hydrochlorothiazide cinfa may affect the mechanism of action of these medicines.
• Treating heart rhythm disorders, such as mizolastine, pentamidine, terfenadine, dofetilide, ibutilide, or erythromycin injections.
• Treating HIV/AIDS (e.g., ritonavir, indinavir, nelfinavir).
• Treating fungal infections (e.g., ketoconazole, itraconazole, amphotericin).
• Treating heart problems, such as quinidine, hydroquinidine, disopyramide, amiodarone, sotalol, bepridil, or digitalis.
• Treating cancer, such as amifostine, cyclophosphamide, or methotrexate.
• Increasing blood pressure and decreasing heart rate, such as noradrenaline.
• Treating gout, such as probenecid, sulfinpyrazone, and allopurinol.
• Lowering blood fat levels, such as cholestyramine and colestipol.
• Lowering blood sugar levels, such as metformin or insulin.

Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicine.

Taking olmesartan/amlodipine/hydrochlorothiazide cinfa with food, drinks, and alcohol

Olmesartan/amlodipine/hydrochlorothiazide cinfa can be taken with or without food.

People taking olmesartan/amlodipine/hydrochlorothiazide cinfa should not consume grapefruit or grapefruit juice. Grapefruit and grapefruit juice may increase blood levels of the active ingredient amlodipine, potentially causing an unpredictable increase in the blood pressure-lowering effect of olmesartan/amlodipine/hydrochlorothiazide cinfa.

Be cautious when drinking alcohol while taking olmesartan/amlodipine/hydrochlorothiazide cinfa, as some people may feel faint or dizzy. If this occurs, avoid alcohol.

Elderly patients

If you are over 65 years old, your doctor will regularly monitor your blood pressure each time your dose is increased, to ensure your blood pressure does not drop too low.

Pregnancy and breastfeeding

Pregnancy

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.

Inform your doctor if you are pregnant or think you might be. Your doctor will advise you to stop taking olmesartan/amlodipine/hydrochlorothiazide cinfa before becoming pregnant or as soon as you know you are pregnant, and will recommend an alternative medicine. Use of olmesartan/amlodipine/hydrochlorothiazide cinfa is not recommended during pregnancy, and it must not be taken after the first 3 months of pregnancy, as it may cause serious harm to your baby if used from the third month of pregnancy onward.

If you become pregnant while taking olmesartan/amlodipine/hydrochlorothiazide cinfa, inform and see your doctor immediately.

Breastfeeding

Inform your doctor if you are breastfeeding or planning to breastfeed. It has been shown that amlodipine and hydrochlorothiazide pass into breast milk in small amounts. Olmesartan/amlodipine/hydrochlorothiazide cinfa is not recommended for breastfeeding mothers, and your doctor may choose an alternative treatment if you wish to breastfeed.

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.

Driving and using machines

You may feel drowsy, unwell, dizzy, or have headaches while being treated for high blood pressure. If this happens, do not drive or operate machinery until symptoms have resolved. Consult your doctor.

olmesartan/amlodipine/hydrochlorothiazide cinfa contains sodium.

This medicine contains less than 23 mg of sodium (1 mmol) per tablet; hence, it is essentially “sodium-free”.

3. How to take/use Olmesartan / Amlodipine / Hydrochlorothiazide Cinfa

Follow exactly the administration instructions for this medicine as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.

• The recommended dose is one tablet per day.

• Tablets can be taken with or without food. Swallow the tablets with some liquid (such as a glass of water). Do not chew the tablet. Do not take the tablets with grapefruit juice.

• If possible, take your daily dose at the same time each day, for example at breakfast time.

• If you take more Olmesartán/Amlodipino/Hidroclorotiazida Cinfa than you should

• If you take more tablets than you should, you are likely to experience a drop in blood pressure, accompanied by symptoms such as dizziness, or fast or slow heartbeat.

• If you take more tablets than prescribed, or if a child accidentally ingests any tablets, contact your doctor immediately or go to the nearest emergency department, and bring the medicine package or this leaflet with you.

• Excess fluid may accumulate in the lungs (pulmonary edema), causing difficulty in breathing, which may develop within 24–48 hours after ingestion.

• In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Poison Information Service at telephone number 91 562 04 20.

• If you forget to take Olmesartán/Amlodipino/Hidroclorotiazida Cinfa

• If you forget to take a dose, take your usual dose the next day. Do not take a double dose to make up for missed doses.

• If you stop taking Olmesartán/Amlodipino/Hidroclorotiazida Cinfa

• It is important to continue taking this medicine unless your doctor tells you to stop.

• If you have any further questions about the use of this medicine, ask your doctor or pharmacist.

4. Possible adverse effects

Like all medicines, this medicine may cause adverse effects, although not everyone will experience them. If they do occur, they are often mild and do not require discontinuation of treatment.

The following adverse effects may be serious, although they affect only a small number of people:

During treatment with olmesartan/amlodipine/hydrochlorothiazide, allergic reactions may occur, with swelling of the face, mouth and/or larynx (vocal cords), together with itching and skin rash. If this happens to you, stop taking this medicine and consult your doctor immediately.

Olmesartan/amlodipine/hydrochlorothiazide may cause a marked drop in blood pressure in susceptible patients. This may lead to fainting or severe dizziness. If this happens to you, stop taking this medicine, consult your doctor immediately, and remain lying down in a horizontal position.

Frequency not known: If you experience yellowing of the whites of the eyes, dark urine, or skin itching—even if you started treatment with olmesartan/amlodipine/hydrochlorothiazide some time ago—contact your doctor immediately, who will evaluate your symptoms and decide how to proceed with your blood pressure treatment.

Olmesartan/amlodipine/hydrochlorothiazide is a combination of three active substances. The following information first describes the adverse effects reported so far with the combination olmesartan/amlodipine/hydrochlorothiazide (in addition to those already mentioned), and secondly, the known adverse effects of each active substance individually, or when two of the substances are taken together.

To give you an idea of how many patients may experience adverse effects, these have been classified as common, uncommon, rare, and very rare.

These are other known adverse effects reported so far with olmesartan/amlodipine/hydrochlorothiazide:

If these effects occur, they are often mild and it is not necessary to discontinue treatment.

Common (may affect up to 1 in 10 people)

Upper respiratory tract infection, sore throat and nasal symptoms, urinary tract infection, dizziness, headache, awareness of heartbeat, low blood pressure, nausea, diarrhea, constipation, cramps, joint swelling, feeling of urgency to urinate, weakness, ankle swelling, fatigue, abnormal laboratory test results.

Uncommon (may affect up to 1 in 100 people)

Dizziness upon standing, vertigo, rapid heartbeat, feeling faint, facial flushing and sensation of warmth, cough, dry mouth, muscle weakness, inability to achieve or maintain an erection.

These are the known adverse effects for each of the active substances individually or when two of the substances are taken together:

These may be adverse effects due to olmesartan/amlodipine/hydrochlorothiazide, even if they have not yet been observed with olmesartan/amlodipine/hydrochlorothiazide.

Very common (may affect more than 1 in 10 people)

Edema (fluid retention).

Common (may affect up to 1 in 10 people)

Bronchitis, stomach and intestinal infection, vomiting, increased blood sugar, sugar in urine, confusion, drowsiness, visual disturbances (including double vision and blurred vision), nasal discharge or congestion, sore throat, difficulty breathing, cough, abdominal pain, heartburn, stomach discomfort, flatulence, joint or bone pain, back pain, bone pain, blood in urine, flu-like symptoms, chest pain, pain.

Uncommon (may affect up to 1 in 100 people)

Reduction in the number of a type of blood cells called platelets, which may cause easy bruising or prolonged bleeding time, anaphylactic reactions, abnormally decreased appetite (anorexia), sleep disturbances, irritability, mood changes including anxiety, feeling of depression, chills, sleep disorders, altered sense of taste, loss of consciousness, reduced sense of touch, tingling sensation, worsening of myopia, ringing in the ears (tinnitus), angina (chest pain or discomfort, known as angina pectoris), irregular heartbeat, rash, hair loss, allergic skin inflammation, skin redness, purple spots or patches on the skin due to small hemorrhages (purpura), skin discoloration, itchy red welts (urticaria), increased sweating, pruritus, skin rash, skin reactions to light such as sunburn or skin eruption, muscle pain, difficulty urinating, feeling of needing to urinate at night, enlargement of the breasts in men, decreased sexual desire, facial swelling, feeling of malaise, weight gain or weight loss, exhaustion.

Rare (may affect up to 1 in 1,000 people)

Inflammation and pain of the salivary glands, decreased number of white blood cells in the blood, which could increase the risk of infections, decreased number of red blood cells (anemia), bone marrow damage, restlessness, feeling of loss of interest (apathy), seizures, yellowish perception of objects when looking at them, dry eyes, blood clots (thrombosis, embolism), fluid accumulation in the lungs, pneumonia, inflammation of blood vessels and small blood vessels in the skin, inflammation of the pancreas, yellowing of the skin and eyes, acute inflammation of the gallbladder, symptoms of systemic lupus erythematosus such as skin rash, joint pain, and coldness in hands and fingers, severe skin reactions including intense skin rash, urticaria, redness of the skin, severe itching, blisters, peeling and inflammation of the skin, inflammation of mucous membranes (Stevens-Johnson syndrome, toxic epidermal necrolysis), sometimes very severe, deterioration in movement, acute renal failure, non-infectious inflammation of the kidney, decreased kidney function, fever, intestinal angioedema: swelling in the intestine causing symptoms such as abdominal pain, nausea, vomiting, and diarrhea.

Very rare (may affect up to 1 in 10,000 people)

Increased muscle tension, numbness of hands or feet, heart attack, inflammation of the stomach, gum overgrowth, intestinal obstruction, liver inflammation.

Acute breathing difficulty (symptoms include severe shortness of breath, fever, weakness, and confusion).

Adverse effects with unknown frequency (cannot be estimated from the available data)

Decreased vision or eye pain due to elevated pressure [possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma], tremors, rigid posture, mask-like face, slow movements, and unbalanced gait with shuffling steps.

Skin and lip cancer (non-melanoma skin cancer).

Reporting of adverse effects

If you experience any adverse effect, consult your doctor or pharmacist, even if they are possible adverse effects not listed in this leaflet. You may also report them directly via the Spanish Pharmacovigilance System for Human Medicines: www.notificaram.es. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of olmesartan/amlodipine/hydrochlorothiazide cinfa

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the packaging after EXP. The expiry date refers to the last day of the month indicated.

No special storage conditions are required.

Medicines must not be disposed of via wastewater or household waste. Dispose of containers and unused medicines at the SIGRE Point located at your pharmacy. If in doubt, ask your pharmacist how to dispose of containers and medicines you no longer need. This will help protect the environment.

6. Contents of the pack and other information

Composition of olmesartan/amlodipine/hydrochlorothiazide cinfa

• The active substances are olmesartan medoxomil, amlodipine (as amlodipine besilate) and hydrochlorothiazide. Each film-coated tablet contains 40 mg of olmesartan medoxomil, 10 mg of amlodipine (as amlodipine besilate) and 12.5 mg of hydrochlorothiazide.

• The other components are:

Tablet core: Pregelatinized corn starch, microcrystalline cellulose, sodium croscarmellose and magnesium stearate.

Tablet coating: Red iron oxide and Opadry White (polyvinyl alcohol, polyethylene glycol, titanium dioxide and talc).

Appearance of the product and contents of the container

olmesartan/amlodipine/hydrochlorothiazide cinfa 40 mg/10 mg/12.5 mg: film-coated tablets, cylindrical, biconvex, pink in colour, with the logo “t3” on one side.

Presented in blister packs containing 28 tablets.

Marketing Authorization Holder and Manufacturer

Laboratorios Cinfa, S.A.
Carretera Olaz Chipi, 10. Polígono Industrial Areta
31620 Huarte (Navarra) – Spain

Date of the most recent revision of this leaflet: February 2025

Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/)

You can access detailed and up-to-date information about this medicine by scanning with your mobile phone (smartphone) the QR code included in the package leaflet and outer packaging. You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/84677/P_84677.html

QR code to: https://cima.aemps.es/cima/dochtml/p/84677/P_84677.html